Intellia Therapeutics
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Intellia Therapeutics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Intellia Therapeutics: 3 sponsored US clinical trials, none currently recruiting.
Intellia Therapeutics sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, with 1 trials.
Upper-quartile sponsor footprint
Intellia Therapeutics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
NCT05066165
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
How the Intellia Therapeutics archive is shaped
3 indexed studies, none listed as recruiting (0% open).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Intellia Therapeutics: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Intellia Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Intellia Therapeutics page
3 registered trials is a research-attention snapshot, not an endorsement of Intellia Therapeutics or any single study.
- None of Intellia Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy is the condition Intellia Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Transthyretin Amyloidosis (ATTR) With Cardiomyopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Intellia Therapeutics pipeline card: 3 registered trials from official public datasets.Report a data error.